Diagnosis progress and treatment standard of post-transplantation lymphoproliferative diseases
10.3760/cma.j.issn.1009-9921.2017.08.016
- VernacularTitle:移植后淋巴细胞增殖性疾病诊断进展与治疗规范
- Author:
Zhanxiang LIU
- Keywords:
Post transplant lymphatic proliferative disease;
Diagnosis;
Therapy
- From:
Journal of Leukemia & Lymphoma
2017;26(8):502-505
- CountryChina
- Language:Chinese
-
Abstract:
Post-transplantation lymphoproliferative diseases (PTLD) is a kind of lymphoproliferative disease caused by immune deficiency after hematopoietic stem cell transplantation and solid organ transplantation, and characterized by poor prognosis. Its major pathogenesis is associated with EB virus (EBV), which means immune monitoring in the condition of immune deficiency generates abnormal hyperplasia and transformation of B-cell infected by EBV. The clinical manifestations include fever, pharyngitis, lymphadenopathy, hepatosplenomegaly and other nonspecific symptoms. Supplementary examination refers to EBV, and definite diagnosis requires histopathology results. Pathological classification of PTLD includes early lesion, polymorphic lesion, monomorphic lesion, and Hodgkin's lymphoma. Management of EBV infection and EBV related to PTLD after transplantation is divided into 3 levels: prevention of EBV activation, preemptive treatment and target therapy. Fortunately, rituximab being a B-cell targeted drug has gained an increasing application.
